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Non-steroidal anti-inflammatory drug
induced acute kidney injury in the
community dwelling general population
and people with chronic kidney disease:
systematic review and meta-analysis
Xinyu Zhang1, Peter T Donnan1, Samira Bell2 and Bruce Guthrie1*
Abstract
Background: Non-steroidal anti-inflammatory drugs (NSAIDs) are a common cause of adverse drug events (ADEs), but
renal risks of NSAIDs are less well quantified than gastrointestinal and cardiac risks. This paper reports a systematic
review of published population-based observational studies examining the risk of acute kidney injury (AKI) associated
with NSAIDs in community-dwelling adults and those with pre-existing chronic kidney disease (CKD).
Methods: MEDLINE and EMBASE databases were searched until June 2016, and 3789 papers screened. Ten studies
reporting NSAID risk of AKI in the general population were included in random effects meta-analysis, of which five
additionally reported NSAID risk in people with CKD.
Results: In the general population, the pooled odds ratio (OR) of AKI for current NSAID exposure was 1.73 (95%CI 1.44
to 2.07), with somewhat higher risk observed in older people (OR 2.51, 95%CI 1.52 to 2.68). In people with CKD,
individual study OR of AKI due to current NSAID exposure ranged from 1.12 to 5.25, with pooled estimate OR 1.63
(95% CI 1.22 to 2.19).
Conclusions: No study reported baseline risk of AKI in different populations meaning absolute risks could not be
estimated, but baseline risk and therefore the absolute risk of NSAID exposure is likely to be higher in people with CKD
and older people. Large population based studies measuring AKI using current definitions and estimating the absolute
risk of harm are needed in order to better inform clinical decision making.
Keywords: Acute kidney injury, Chronic kidney disease, Non-steroidal anti-inflammatory drugs, Pharmacoepidemiology
Background
Non-steroidal anti-inflammatory drugs (NSAIDs) are
commonly prescribed in primary care for their analgesic,
antipyretic and anti-inflammatory effects. One in fifteen
US adults are actively prescribed NSAIDs at any one
time [1], and in many countries low-dose preparations
are also available over-the-counter (OCT). Partly due to
their widespread use, NSAIDs account for 25% of adverse
drug events (ADEs) reported in the United Kingdom (UK)
and 21% in the United States (US) [2, 3]. NSAIDs are also
commonly implicated in hospital admissions due to ADEs,
including those which are fatal [4], but gastrointestinal
and cardiac toxicity are better quantified than renal tox-
icity [5].
NSAIDs can reduce renal blood flow, cause tubular
obstruction through crystal deposition, and induce direct
cytotoxicity and cell-mediated immune injury mechanisms
leading to the occurrence of acute kidney injury (AKI). An-
other symptom that is commonly caused by NSAIDs is
interstitial nephritis (AIN) which requires specialist review,
renal biopsy, high-dose corticosteroid and/or immunosup-
pressant treatments, and will normally be progression in
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chronic kidney disease (CKD) [6]. Older age [7, 8] and
underlying chronic kidney disease are also related to the
onset of AKI during NSAID use, with early studies show-
ing that the risk of deterioration in renal function increases
3–4 fold in patients with abnormal baseline renal function
compared to those with normal renal function [9]. Notably,
NSAIDs are commonly prescribed to people with CKD,
despite guidance to avoid them in this population. In US
veterans in 2005, 15.4% of people with CKD were pre-
scribed traditional NSAIDs or COX-2 inhibitors [10], com-
pared to 11.1% of people with CKD in the UK in 2012 [11],
and 15.9% of people with CKD in Australia in 2004–2006
[12]. Better quantification of risk in people with CKD is
therefore of particular clinical interest, as is whether
NSAID risk varies by age and by COX-2 selectivity. In
terms of COX-2 selectivity, early studies suggested that
COX-2-selective inhibitors caused fewer renal adverse
effects including reduction in glomerular filtration rate
(GFR), increased serum creatinine (SCr) and hyperten-
sion [13–15]. Other studies have shown no significant
differences in renal risk between COX-2-selective in-
hibitors and nonselective NSAIDs [16, 17].
There is little evidence about the risk of AKI associ-
ated with NSAID use in people with CKD available from
randomised trials of NSAIDs because such trials rou-
tinely exclude people with CKD and rarely report renal
outcomes [18]. Under these circumstances, observational
evidence provides the best guide to practice that exists.
The aim of this study is to systematically review published
high-quality population-based observational studies to
quantify the risk of AKI due to NSAIDs in the general
population and in people with pre-existing CKD.
Methods
Data sources and search strategy
MEDLINE and EMBASE were systematically searched
from inception to June 21th 2016 using OVID from the
Knowledge Network using a predetermined list of key-
words including NSAIDs, renal diseases and renal function
measurements modified from the search strategies used by
two related Cochrane reviews (see Additional file 1 for
search strategy) [18, 19]. Search results were restricted to
cross-sectional, cohort and case-control studies in the
English language. The reference lists from all identified
primary studies, review articles, Kidney Disease Improving
Global Outcomes (KDIGO) clinical practice guidelines for
CKD and AKI and OpenSIGLE (unpublished literature
database) were manually checked to screen for additional
relevant papers.
Citations were independently screened for eligibility by
two reviewers based on title and abstract (XZ and SB or
XZ and BG). If one or more authors deemed the study
potentially relevant, or if there was any uncertainty
about eligibility based on title and abstract alone, then
the full text paper was retrieved for review. Authors of
original studies were not contacted. Study selection and
quality assessment from full-text papers retrieved were
performed independently by two reviewers (XZ and BG).
Study selection
The search strategy and data extraction were defined in
a PICOS format (participants, intervention, comparison,
outcome and study design). Studies published in English
were eligible for inclusion when they used observational
methods to study adults in the community exposed to
NSAIDs and reported AKI as an outcome. Given the
historical lack of consensus on AKI definition, studies
using a variety of definitions of AKI were included, with
AKI defined by International Classification of Diseases
(ICD) 9 or 10 codes, or change in eGFR or creatinine clear-
ance (CrCl) or serum creatinine (SCr). Similarly, varying
definitions of CKD were allowed including estimated
GFR < 60 ml/min (with or without standardization to body
surface area), or based on ICD codes, or SCr > 122 μmol/L,
or structured patient interview. Traditional NSAIDs and
COX-2 inhibitors were included with the exception of low
dose aspirin (<300 mg per dose) [20]. Studies were ex-
cluded if they were published in abstract only, included
children (age < 18 years old), only included post-operative
patients or others receiving only one or two doses of
NSAID as treatment (e.g. for renal colic or post-lithotripsy),
or had end-stage renal disease defined as being on dia-
lysis or having received a renal transplant. Finally,
meta-analyses, studies with <100 subjects, and studies
without a contemporaneous control group drawn from
the same population were excluded.
Data extraction and quality/validity assessment
Data were extracted into a standardised form and checked
for accuracy by a second reviewer. When data were re-
ported in strata, the data were extracted as separate
subgroups. The following data were extracted for each
included study: author, publication year, study design,
population (data source, sample size, location, age, gen-
der and underlying renal conditions), definition of AKI,
inclusion criteria, exclusion criteria, medication exposure
(type of NSAID), period and length of NSAID usage,
number of people who were and were not exposed to
NSAIDs, as well as crude unadjusted and adjusted associa-
tions between NSAID use and outcomes. The quality of
the included studies was evaluated in three domains
using the validated Newcastle-Ottawa Quality Assess-
ment Scale for cohort and case-control studies [21], with
each item rated as either one star or missing (Table 1).
Disagreements were resolved by discussions with two
authors (XZ and BG) and a third reviewer was involved
where required (PTD).
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Statistical analyses
The outcome was the presence or not of AKI. In studies
among the general population, adjusted odds ratio (OR)
with 95% confidence intervals (CI) for AKI with NSAID
exposure were pooled using the generic inverse variance
method which assumed weights equivalent to inverse of
variance of individual estimates [22, 23]. This was be-
cause adjusted ORs and CIs were mostly presented in
the primary studies while raw ORs and CIs were not.
Moreover, pooled results will be more meaningful with
the adjustment. When calculating the pooled result, in
order to be more conservative, the individual OR with the
most extreme of the lower or higher side of the CI for
each study was used to estimate the variance. Additional
subgroup meta-analyses were conducted to explore het-
erogeneity stratified according to pre-specified study-level
covariates namely age and COX-2 selectivity.
In all but one case, primary studies which included
analysis for the subgroup of people with CKD did not
provide adjusted estimates of association. Therefore crude
ORs and CIs from the raw data were calculated, and
pooled using Mantel-Haenszel method.
A random-effects model was used for all analyses, and
heterogeneity between studies assessed by the I2 statistic
and the χ2 test for heterogeneity. I2 is the percentage of
variance that is due to between-study variance and is an
indicator of consistency between studies. Values of 25–
50%, 50–75% and >75% were considered evidence of
mild, moderate and marked heterogeneity, respectively
[24]. Publication bias was not assessed because of the
extensive statistical heterogeneity found, since such het-
erogeneity in itself may lead to funnel plot asymmetry
[25]. AKI is an uncommon adverse event and it was
assumed that the OR was an accurate estimate of the
relative risk (RR) of AKI in NSAID users compared with
non-users.
Statistical analyses were performed using Review
Manager 5.2 (Cochrane Collaboration, Oxford, United
Kingdom). Statistical significance was set at P < 0.05
for all analyses. This systematic review was structured
in accordance with the Meta-analysis of observational
studies in epidemiology (MOOSE) statement (Additional
file 2) [26].
Results
Study flow and characteristics
Electronic searches retrieved 4629 citations, with 3789
unique citations screened and four studies [27–30] iden-
tified from other sources (Fig. 1). After title and abstract
screening 30 full-text studies were reviewed of which 10
studies published between 1990 and 2012 met the inclu-
sion and quality criteria and were included (details for
excluding were recorded in Additional file 3). All 10
studies examined NSAID-associated AKI risk in the
general population with a total of 1,609,163 participants
[6, 8, 9, 31–37]. Five of these studies also provided data
in the subset of people with CKD [31–33, 35, 37].
Eighty percent of studies were rated with seven or more
stars out of a possible nine on the Newcastle-Ottawa
quality assessment scale (Table 1). Hence the quality
of the included studies was considered to be medium
to high.
In all included studies, eligible cases with AKI were re-
cruited in a defined catchment area over a defined period
of time, the ascertainment of exposure was through secure
electronic records and the same method of ascertainment
Table 1 Quality assessment
aIf cases are first occurrence of outcome, then it must explicitly state that controls have no history of this outcome. If cases have new (not necessarily first)
occurrence of outcome, then controls with previous occurrences of outcome of interest will not be excluded
b = same non-response rate for both groups reported ; NP = not reporting non-response rate is Not a Problem (since bias is less likely if the cases and controls
come from the same population and have outcomes and exposures ascertained in the same way)
cCC case-control, N-CC nested case-control
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was used among cases and controls. Eighty percent of the
included studies had independent validation of cases while
the remaining 20% relied on record linkage alone (ICD
codes in database) with no reference to the primary
record. One study [33] used hospital controls as their
cases were people with community exposure to NSAIDs
admitted to hospital with AKI. Two studies [34, 37] used a
mixture of hospitalized and community controls. The
other included studies selected controls from community
or reported hospital and community controls separately in
which case only comparisons with community controls
were included. The history of outcome occurrence in
cases and controls were adequate in 90% of the studies.
Two included studies did not match for age and other
factors among cases and controls while one of them ad-
justed for a list of confounders including sex and use of
prescription of acetylsalicylic acid (ASA) in current use
of any NSAID.
Table 2 summarises the 10 included nested case-control
and case-control studies (five each), of which five involved
participants from North America, four from Europe and
one from Australia. Nine studies used data extracted from
routine electronic databases while the Australian study
[33] combined electronic data with structured patient
interviews. One study population comprised patients tak-
ing angiotensin-converting-enzyme inhibitor (ACE inhibi-
tors) and the others were of the general adult population
[8]. Seventy percent of the studies focused on older partic-
ipants (either only including older participants or where
the mean/ median age of participants was >65 years) while
gender proportions among included studies were diverse.
Current or new use of NSAIDs as reported by the original
study authors was used as the exposure definition (70% of
studies reported exposure to NSAIDs 0–90 days prior to
the index day for the adverse event, other studies did not
specify). One study only examined ibuprofen [9], but most
examined exposure to a variety of NSAIDs. Half of the
studies used laboratory data to define the presence of AKI,
whereas varying sets of hospitalisation discharge diagnosis
ICD codes were used in the other half. Each of the studies
adjusted for a list of confounders. Newer studies tended to
have a more thorough adjustment. The most common
confounders studies adjusted for general polulation are
age, gender, comorbidity (such as hypertension, diabetes,
heart failure, and cardiovascular disease), concomitant drug
use (such as diuretics, antibiotics, radio contrast ex-
posure, and nephrotoxic drugs), and hospitalization
(Table 3).
Fig. 1 Flow diagram of the identification process for eligible studies
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Association between NSAID exposure and AKI in the
general population
Ten studies that included a total of 1,609,163 partici-
pants were used to evaluate AKI risk among current
NSAID users in the general population (Fig. 2). The ad-
justed OR for AKI was increased relative to non-users
and between individual studies ranged from 1.05 to 4.10,
with eight of the ten studies showing a statistically sig-
nificant association between NSAID exposure and AKI.
Meta-analysis of adjusted odds ratios estimated the
pooled OR to be 1.73 (95%CI 1.44–2.07). Heterogeneity
was substantial (I2 = 89%, P < 0.001), suggesting that the
pooled estimate should be interpreted with caution.
Association between NSAID exposure and AKI in people
with CKD
Two case-control and three nested-case-control studies
which included 106,681 people with CKD reported data
that could be used to evaluate AKI risk by current
NSAID exposure. The crude OR for AKI in NSAID
users compared with nonusers ranged from 1.12 to 5.25
and was >1 and statistically significant in 4 of 5 studies
(Fig. 2). The pooled crude OR was 1.63 (95% CI 1.22–
2.19) and I2 statistic was 71% (P = 0.009). We noted
weaker associations with AKI in larger studies with more
precise estimates of risk, with the two studies reporting
the largest risks being older, smaller and less precisely
estimated.
Subgroup analyses
To explore heterogeneity, we examined association with
AKI in older users of NSAIDs (age > 50 years), stratified
by COX-2 selectivity of the NSAIDs exposed to [38]
(none, <5-fold and ≥5-fold), and in older patients with
exposure to COX-2 selective NSAIDs (Figs. 3, 4 and 5).
Statistical heterogeneity remained in subgroup analyses
but it was modestly reduced, suggesting that subgroup
analyses provided more confidence in the pooled esti-
mates, but interpretation of pooled estimates should still
be cautious.
The pooled results of NSAIDs with different COX-2
selectivity for AKI are shown in Fig. 3. Similar to the
general results, there were increased associations between
AKI and exposure to NSAIDs with different COX-2
Table 3 Confounders that the included studies adjusted for
First Author, Year Confounders adjusted in general population
Bouvy 2003 [8] Age and gender, prior hospital admissions for congestive heart failure, diabetes and for concomitant use of diuretics,
low-dose aspirin, antibiotics, paracetamol (acetaminophen), epoetin, corticosteroids, opioids, digoxin, antigout drugs
and duration of use of ACE inhibitor
Huerta 2005 [34] Sex, age, calendar year, body mass index, HF, hypertension, diabetes, antihypertensive use, oral steroid use, NSAID use,
and consultant visits and hospitalizations in the previous year
Leonard 2012 [6] Hospitalized in prior 30 days, ever past anemia, ever past coronary disease, ever past heart failure/cardiomyopathy,
ever past disorders of stomach function, ever past arthropathies and related disorders, ever past pain, ever past
gastrointestinal drug use, ever past cardiovascular system drug use, ever past central nervous system drug use, ever
past infection-treating drug use, ever past endocrine system drug use, ever past nutrition and blood drug use, ever
past musculoskeletal and joint disease drug use, frusemide use in the prior 28 days, and kidney sensitizer drug
exposure in the prior 180 days
Murray 1990 [9] Age, gender, race, coronary artery disease, baseline systolic blood pressure, diuretic use,
Perez Gutthann 1996 [36] Age, sex, calendar year, cardiovascular risk indicator, recent hospitalization for disorders renal, exposure to NSAIDs,
prescription ASA, nephrotoxic drugs
Evans 1995 [31] Age, gender, could not find information in other covariates
Griffin 2000 [32] Age (65–74, 75–84, > = 85), gender, ethnicity, nursing home resident, recent hospitalization (within 30 days,
31–365 days, none in the past year), concomitant use of loop diuretic, thiazide, ACE inhibitor, and antibiotics
(within 30 days), prescription for allopurinol, cyclosporin, gold, sulfinpyrazone, or penidllamine, first prescription
for cimetidine in the past 60 days, or procedure code Indicating intravenous radio contrast within the past 30 days
Schneider 2006 [37] Age, gender, comorbidity (Hypertension, Diabetes, Heart failure, Cardiovascular disease, Atherosclerosis, Hyperlipidemia,
Respiratory disease, Gastrointestinal ulcer disease, Chronic renal failure, Acute renal failure, Renal disease, Renovascular
disease, Renal infection, Conditions secondary to renal impairment, Renal manifestation of systemic diseases, Systemic
disease and malignancy relevant to renal function), drug use (Oral anticoagulants, Oral corticosteroids, Psychotropic
drugs, Thyroid drugs. Current use of aspirin, Use of nephrotoxic drugs, Exposure to contrast media), comorbidity
measures (No. of different drugs, Chronic disease score, Charlson index, Health care utilization (>12 physician visits,
> = 1 nephrologist visits >1 hospitalization))
Lafrance 2009 [35] Age, gender, race, concurrent disease (Arrhythmia, Chronic kidney disease, Cardiovascular disease, Cancer, Chronic liver
disease, Chronic pulmonary disease, Congestive heart failure, Diabetes, Hyperlipidemia, Hypertension, Osteoarthritis,
Rheumatoid arthritis, Peptic ulcer/ GERD, PVD, Valvular disease), hospitalization (last 30 days, previous year), drug use
(ACEi or ARBs, Beta-blockers, Diuretics, Oral anticoagulants, Platelet aggregation drugs, Nephrotoxic drugs, Corticosteroids,
Radio contrast exposure), laboratory (Serum albumin)
Henry 1997 [33] Age, history of gout, heart disease and renal disease
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selectivity (no COX-2 selectivity 1.84, 95%CI 1.54–2.19,
COX-2 selectivity <5-fold 1.43, 95%CI 1.25–1.64 and
COX-2 selectivity ≥5-fold 1.41, 95%CI 1.07–1.87). There
was a non-statistically significant trend that the higher the
COX-2 selectivity NSAIDs was, the lower the increased
odds of AKI (subgroup difference test χ2 = 5.31, df = 2,
P = 0.07).
Older people (>50 years) using NSAIDs had a some-
what higher odds of AKI associated with NSAID expos-
ure than the general population (2.01, 95%CI 1.52–2.68;
Fig. 4), although the confidence intervals overlap, and
there was again significant heterogeneity (I2 = 62%). In
older people who were using NSAIDs with COX-2 se-
lectivity, the odds ratio was 1.73 (95%CI 1.32–2.29;
Fig. 5) which is similar to the general population. Het-
erogeneity was moderate (45%) in this subgroup.
Discussion
The results of the meta-analysis showed that current ex-
posure to NSAIDs was associated with an approximately
1.5-fold increase in the odds of developing AKI in the
general population and in people with CKD. Since AKI
is a rare NSAIDs associated adverse outcome, odds ra-
tios will approximate to relative risks. There was con-
siderable heterogeneity between studies, particularly in
the general population group and so the pooled esti-
mates should be interpreted with caution. The limited
numbers of studies eligible for inclusion precluded
meta-regression, so subgroup analyses were conducted
in order to try to explore and explain heterogeneity. Re-
sults were consistent with and similar to the main find-
ings. Older people who were prescribed NSAIDs had a
somewhat higher (2-fold) risk of developing AKI, but
there was no strong evidence that greater COX-2 selectiv-
ity was associated with lower AKI risk. NSAIDs with high
COX-2 selectivity (≥5-fold) had a lower association with
AKI than NSAIDs with COX-2 selectivity <5-fold, and
heterogeneity in the subgroups was reduced compared to
the overall results consistent with some of the heterogen-
eity being due to differences in the age of the population
studies and the type of NSAIDs examined. Five studies in-
cluded individual NSAID usage in their analyses in which
only Lafrance and Schneider compared dose effect in
Rofecoxib, Celecoxib, Naproxen and Meloxicam (Lafrance
only) [9, 32, 34, 35, 37]. Dose response cannot be easily
stratified as higher dosage will be associated with a higher
risk of effect compared to lower dosage but the exposure
window is not under control. However, other differences
in population and in AKI definition were substantial and
likely accounts for much of the observed heterogeneity.
Overall, all analyses showed a statistically significant, mod-
estly increased risk of AKI from exposure to NSAIDs, and
the magnitude of the increased risk of AKI was rather
similar among all sub-groups with mostly overlapping
confidence intervals.
The study strengths include careful study selection
and the use of a structured quality assessment tool to
ensure that only high quality studies were included [21].
Fig. 2 Pooled odds ratio and 95% confidence intervals for AKI in general population and people with CKD using NSAID vs not using
Zhang et al. BMC Nephrology  (2017) 18:256 Page 8 of 12
The observed associations were consistent across sub-
groups, but the study has several limitations. As with all
systematic reviews, the findings depend on the quality of
the included studies. We chose to review and meta-
analyse observational studies because an initial literature
search identified that trials of NSAIDs rarely report renal
outcomes (the focus of this study) and exclude people
with CKD (a key topic of interest) and other comorbidi-
ties as well as older people and minority groups [18, 39].
However, observational studies are vulnerable to residual
confounding by measured and unmeasured variables. An
example is confounding by indication, which in this
Fig. 4 Pooled odds ratio and 95% confidence interval for AKI in elderly people using NSAIDs vs not using
Fig. 3 Pooled odds ratio and 95% confidence interval for AKI in general population using NSAIDs with different COX-2 selectivity vs not using
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context is likely to occur if prescribers avoid NSAIDs in
people they perceive to be at higher risk of NSAID tox-
icity including AKI, which would lead to an underesti-
mation of AKI risk if present. There were also large
differences between studies in the population examined
and the way in which AKI was measured, both of which
likely contributed to the observed moderate to large het-
erogeneity between studies. It is also important to recog-
nise that the estimate of the risk of NSAIDs in the
general population is adjusted for potential confounders,
but the estimate in people with CKD is not because only
one study reported an adjusted estimate [33]. Other
limitations include that we only included studies pub-
lished in English, that there were a relatively small
number of studies suitable for inclusion which made
meta-regression to explore heterogeneity unfeasible,
and that the rate of concomitant use of OTC NSAID
use could not be assessed in the populations studied.
Seven of the included studies [6, 8, 31, 32, 34, 35, 37]
addressed that OCT NSAID use may have caused expos-
ure misclassification. But all of the studies believed that
due to reasons such as financial incentives, the proportion
of OCT NSAID users is expected to be small and nondif-
ferential with respect to the NSAID categories the popula-
tions studied. Consequently, it would bias the results
toward the null. As most of the studies confirmed eligible
cases then selected controls according to a certain propor-
tion, non-response rate was not given in the majority of
the included studies. Since cases and controls of these
studies were derived from the same databases, were exam-
ined for the same exposure and followed up in the same
way, then non-response rate is not considered to be a
problem and therefore it is unlikely there would be miss-
ing data bias. We were unable to access publication bias
because of the extensive statistical heterogeneity. For
many of the methodological qualities assessed there was
an unclear risk of bias as studies did not provide explicit
detail to make an informed judgement.
To our knowledge, this study is the first meta-analysis
to examine associations between NSAID exposure and
AKI in the general community-dwelling population and
people with CKD. A previous systematic review which
was conducted in 2014 included five observational studies
and reported risk of AKI by individual NSAID exposure,
finding a statistically significant elevated AKI risk among
most of the traditional NSAIDs but did not achieve a stat-
istical significance for COX-2 inhibitors or traditional
NSAIDs with higher COX-2 selectivity (meloxicam and
diclofenac) [40]. Our study used a more comprehensive
search and included additional studies, and found a
similar estimate of pooled risk but statistically significantly
increased risk irrespective of COX-2 selectivity. Another
systematic review specifically focused on myocardial, vascu-
lar and renal risks of COX-2-selective meloxicam allowed a
broad definition of renal outcomes and it did not find a
significantly increased renal risk [41]. A third systematic
review examined the risk of CKD progression associated
with NSAID use, finding that high (but not standard) dose
NSAID use was associated with an increased risk of CKD
progression [42].
Conclusion
AKI is an increasingly common global problem causing
significant morbidity and mortality and with large resource
implications. Exposure to NSAIDS and other nephrotoxic
drugs is an important cause of AKI, but the risk of these
exposures is modified by susceptibilities such as increasing
age and the presence of CKD [43]. This study found that
the odds of developing AKI increased by over 50% in
people who were exposed to NSAIDs in the general popu-
lation and in people with CKD, and in older people the
odds of developing AKI doubled. However, the absolute
risk of developing AKI also depends on the baseline risk of
AKI in the population exposed, which none of the included
studies reported. Future studies should use internationally
agreed definitions of AKI [44] and estimate the absolute
risk of AKI in different populations including older people
and people with CKD to better inform clinical decision
making. There is evidence that feedback and more com-
plex interventions to reduce NSAID prescribing in people
Fig. 5 Pooled odds ratio and 95% confidence interval for AKI in elderly people using NSAIDs with COX-2 selectivity vs not using
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at high risk of renal adverse effects are effective [45, 46],
and clinicians should seek to minimise NSAID expos-
ure in people particularly susceptible to AKI due to
age, CKD or because of the co-prescription of other
nephrotoxic drugs [43, 47].
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